Mana.bio’s founding team (L to R): CTO Roy Nevo, scientific founder Avi Schroeder, CEO Yogev Debbi, and scientific co-founder Kira Radinsky

October 10, 2023 07:00 AM EDTUpdated 03:36 PM

Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver

Ryan Cross

Senior Science Correspondent

One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Little balls of fat called lipid nanoparticles …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ex­clu­sive: An­dreessen Horowitz-backed start­up is us­ing AI to de­sign lipid nanopar­ti­cles that go be­yond the liv­er

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?